Skip to main content
CUVL
NASDAQ Unknown

Clinuvel Files NEURACTHEL® Instant Dossier With EU Regulators

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Positive
Importance info
7
Price
$4.97
Mkt Cap
$260.004M
52W Low
$4.88
52W High
$8.92
52W Position info
1.8% above low
Off High info
44% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CUVL is trading near its 52-week low of $4.88 (1.8% above the low).

Summary

Clinuvel filed its NEURACTHEL® Instant (tetracosactide) marketing-authorisation dossier through Europe's decentralised procedure, targeting up to three EU member states. The product is unapproved anywhere, and the review is expected to take 300 days plus clock stops, with first feedback in around four months.


Key Events · Product Development and Regulatory · CUVL

  • EU Dossier Filed for NEURACTHEL® Instant

    Clinuvel submitted a marketing-authorisation dossier for NEURACTHEL® Instant (tetracosactide), a branded generic synthetic ACTH analogue, via the European decentralised procedure covering up to three initial EU member states.

  • US$1.3B ACTH Market Targeted

    The company estimates the global ACTH market at US$1.3 billion annually and chose launch markets on ACTH usage, prescriber demand, pricing infrastructure and reported shortages, plus overlap with existing SCENESSE® distribution.

  • 300-Day Review, Feedback in ~4 Months

    After dossier validation, the DCP is intended to take 300 days excluding clock stops, with a final position at day 270; management expects first formal feedback in around four months.

  • No Approval Anywhere Yet

    NEURACTHEL® Instant is not currently approved in any country; UK MHRA and additional EU filings are under evaluation, and the US FDA timeline is under review.


Analysis · CUVL · Unknown

Clinuvel has submitted its second pharmaceutical product, NEURACTHEL® Instant, for marketing authorisation in up to three EU member states — the first regulatory filing for a tetracosactide product aimed at a global ACTH market the company sizes at US$1.3 billion a year. Nothing is approved yet, and the decentralised procedure runs 300 review days plus clock stops, with first formal feedback only expected in about four months; this is a pipeline milestone, not revenue. What matters is that it is the first concrete step toward a second commercial product alongside SCENESSE®, and the company says it picked launch markets where existing SCENESSE® distribution can be reused — meaning incremental revenue would come with limited new commercial spend if approval lands.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CUVL was trading at $4.97 on NASDAQ in the Unknown sector, with a market capitalization of approximately $260M. The 52-week trading range was $4.88 to $8.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CUVL - Latest Insights

CUVL
Oct 02, 2026, 11:28 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.03
Real-time Price: $5.09 info
Change: -$0.940 (-16%) info
Market Cap: $253.513M info
CUVL
Aug 27, 2026, 11:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.80
Real-time Price: $5.09 info
Change: -$1.71 (-25%) info
Market Cap: $253.513M info
CUVL
Aug 27, 2026, 1:42 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.62
Real-time Price: $5.09 info
Change: -$2.53 (-33%) info
Market Cap: $253.513M info
CUVL
Jul 28, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $5.09 info
Change: -$1.91 (-27%) info
Market Cap: $253.513M info
CUVL
Jul 23, 2026, 12:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $5.09 info
Change: -$1.91 (-27%) info
Market Cap: $253.513M info